News

ARS Pharmaceuticals Launches neffy in Schools Program for K-12

ARS Pharmaceuticals Launches neffy in Schools Program for K-12

ARS Pharmaceuticals Launches neffy in Schools Program

ARS Pharmaceuticals, a dedicated biopharmaceutical company, has announced an exciting new initiative aimed at enhancing emergency care in K-12 schools across the United States. This program is designed to provide eligible public and private schools with free access to neffy, a needle-free epinephrine nasal spray, which can be crucial for managing severe allergic reactions, especially anaphylaxis. The program is set to kick off in the near future, promoting both safety and accessibility in schools.

Understanding the Importance of neffy

With the alarming statistics related to Type I allergic reactions among children, the need for immediate access to effective treatment has never been more critical. Research indicates that approximately 18% of children with food allergies have experienced allergic reactions at school. Unfortunately, many of these reactions occur in students who have not been previously diagnosed with allergies. This highlights the importance of having emergency treatments like neffy readily available on school premises.

What is neffy?

neffy is a revolutionary intranasal formulation of epinephrine, indicated for emergency treatment of Type I allergic reactions, including anaphylaxis. It is specifically designed for adults and children who weigh over 30 kg (66 lbs). By offering an alternative to traditional auto-injectors, neffy addresses some of the common barriers associated with epinephrine administration, such as fear of needles and disposal challenges.

Program Details and Eligibility

The neffy in Schools program aims to eliminate costs for schools, making it easier for them to stock essential emergency medications. Participating schools will receive two cartons of neffy, which contains four single-use doses. In instances where the medication is used or reaches its expiration date, schools will have the ability to obtain replacements, ensuring continuous support for students in need.

Engaging with Schools

Before the launch of this program, it is crucial for school administrators to familiarize themselves with both federal and state regulations regarding epinephrine stocking. Currently, legislation exists in 49 states and Washington DC, allowing schools to store epinephrine. This proactive step not only empowers schools but also enhances student safety.

Training and Resources for Implementation

Alongside the provision of neffy, ARS Pharmaceuticals plans to support schools with training resources designed for school nurses and administrators. A dedicated webinar will offer detailed insights into the proper use of neffy as well as guidance on managing allergic emergencies effectively. After the official launch, additional instructions will be provided to simplify the process for schools accessing neffy doses.

Safety and Effectiveness of neffy

The efficacy of neffy in providing immediate intervention during allergic reactions cannot be understated. Due to its needle-free nature, it minimizes safety concerns associated with needles, making it more accessible for young patients and those who may be anxious about injections. With a shelf life of 30 months, neffy is designed to remain effective for extended periods, contributing to better preparedness in schools.

About ARS Pharmaceuticals

ARS Pharmaceuticals has made it its mission to empower patients and caregivers to protect against severe allergic reactions. By commercializing neffy, the company aims to make critical treatment readily available, especially in environments frequented by children. As an innovative biopharmaceutical company, ARS is continuously seeking to solve challenges presented by allergic conditions.

Frequently Asked Questions

1. What is the neffy in Schools program?

The neffy in Schools program provides free cartons of neffy to eligible K-12 schools, offering life-saving treatment for allergy emergencies.

2. Who qualifies for receiving neffy under this program?

Eligible public and private K-12 schools in the U.S. can apply for the neffy program.

3. What are the benefits of using neffy?

neffy is a needle-free epinephrine spray, making it easier and safer for administration in emergency situations.

4. How will schools receive training for using neffy?

ARS Pharmaceuticals will provide training through webinars and additional resources for school nurses and administrators.

5. What should schools check before implementing the program?

Schools are encouraged to review local regulations to ensure compliance with laws governing epinephrine stocking and administration.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 104

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 163

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
Community in Shock After Fatal Bakersfield Shooting

Updated Category News Views 98

The Ripple Effect of Tragedy Grief has a way of shaking a community down to its core—especially when the loss emanates from such senseless violence as the shooting death of 17-year-old Levi Brown. This wasn't just a tragic occurrence at a Friday night football game in Bakersfield; it was a visceral crack in the perceived safety of community events. Levi's Legacy and...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 149

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 421

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 339

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 176

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 252

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Fluence Energy Hits Legal Snag: Investors Called to Act

Updated Category News Views 71

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 230

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading

Top 5 Most Recently Viewed Articles

Macao's 25-Year Journey: Celebrating Growth and Prosperity

Updated Category News Views 161

Macao's Remarkable Development Over 25 Years In a vibrant celebration of progress, Macao recently marked the significant milestone of its 25th anniversary since its return to the motherland. A special publication by an English-language newspaper highlighted various achievements that the region has made during this transformative period. Economic Growth and Transformation...

Continue Reading
Opportunity to Address Losses: Join Tempus AI Class Action

Updated Category News Views 128

Investors Encouraged to Participate in Tempus AI Class Action The law firm Robbins Geller Rudman & Dowd LLP is actively reaching out to investors of Tempus AI, Inc. (NASDAQ: TEM) who have experienced notable financial losses. They have announced an opportunity for eligible investors to take the lead in an associated class action lawsuit. This potential action stems from...

Continue Reading
Muncy Columbia Financial Corporation's Strong Q4 2024 Earnings

Updated Category News Views 99

Muncy Columbia Financial Corporation's Financial Outlook Muncy Columbia Financial Corporation (“Corporation”) (OTCQX: CCFN), after releasing its unaudited consolidated financial statements for the fourth quarter of 2024, has demonstrated significant improvement over the previous year. Fourth Quarter 2024 Financial Highlights For the quarter ending December 31, 2024,...

Continue Reading
Caris Life Sciences Expands Cancer Research Alliance

Updated Category News Views 119

Caris Life Sciences Expands Cancer Research Alliance Caris Life Sciences® (NASDAQ: CAI), a forefront player in precision medicine and next-generation AI TechBio, is excited to share the arrival of Providence Swedish Cancer Institute into the esteemed Caris Precision Oncology Alliance (Caris POA). This addition enhances their collective mission to revolutionize cancer...

Continue Reading
Zumiez Inc. Gears Up for First Quarter 2025 Financial Report

Updated Category News Views 263

Upcoming Financial Report for Zumiez Inc. Zumiez Inc. (NASDAQ: ZUMZ) has recently made an exciting announcement regarding its financial performance. The company is set to release its first quarter results for fiscal 2025 on June 5, after the stock market closes. This pivotal moment is eagerly anticipated by investors and stakeholders alike, as it will provide valuable...

Continue Reading